In a recent report, researchers reported pooled data from 2 studies to explore the efficacy of zanubrutinib monotherapy in relapsed/refractory (R/R) mantle cell lymphoma (MCL).
MCL almost always relapses, and before the advent of Bruton tyrosine kinase (BTK) inhibitors, therapeutic options were limited. Zanubrutinib is a next-generation, targeted, and potent BTK inhibitor approved by the FDA in 2019. Besides being approved for MCL, it is also approved for Waldenström macroglobulinemia.
A total of 112 patients were included in the 2 studies, 33 from BGB-3111-AU-003 and 79 from BGB-3111-206; these 2 studies were used in its 2019 US approval. Researchers used patient-level data from the phase 1 and 2 trials to add additional knowledge about zanubrutinib’s efficacy.
Median follow-up durations were 24.7 and 24.9 months for BGB-3111-AU-003 and BGB-3111-206, respectively.
Overall, across the 2 trials, 77% of the patients were male with a mean age of 61.5. Most had advanced disease (stage III or stage IV). A little more than half had bone marrow involvement, while 8% had bulky disease and 13% had blastoid variant.
Most also had low-to-intermediate MCL International Prognostic Index (MIPI) risk scores (79%).
Before weighting, there were 41 patients in the second-line group and 71 patients in the later-line group. Compared with the later-line group, patients in the second-line group had higher age, body mass index (BMI) and a higher percentage with high MIPI risk scores and lower percentages with extra nodal disease and blastoid subtype.
After weighting, covariates were balanced between the 2 groups.
The effective sample sizes were 27 in the second-line group and 59 in the later-line group, with median treatment durations of 22 and 18.8 months, respectively.
After weighting, the progression-free survival (PFS; median, not estimable [NE] vs. 21.1 months, P = .235) and overall survival (OS; median, NE vs. 38.2 months, P = .057) were similar but numerically better in the second-line than later-line group.
In second- and later-line therapy groups, prior treatment regimens included:
The percentage of patients who received prior bendamustine was low in both groups (4% in second-line and 5% in later-line).
Overall response rate (ORR) and complete response (CR) rate were 84.8% and 62.5%.
Median duration of response, PFS, and OS were 24.9, 25.8 and 38.2 months, respectively.
The authors said zanubrutinib was well-tolerated. Treatment discontinuation and dose reduction for adverse events (AEs) were 12.5% and 2.7% of patients, respectively.
Hypertension, major hemorrhage and atrial fibrillation/flutter rates were 11.6%, 5.4% and 1.8%, respectively.
Reference
Zhou K, Zhou D, Zhou J, et al. Zanubrutinib monotherapy in relapsed/refractory mantle cell lymphoma: a pooled analysis of two clinical trials. J Hematol Oncol. Published online October 14, 2021. doi: 10.1186/s13045-021-01174-3.
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Study Highlights Significant Increases in Utilization, Spending on DMD Drugs in Medicaid
May 17th 2024The findings add to recent research on the growing utilization, expenditure, and prices of Duchenne muscular dystrophy (DMD) therapies in the current landscape, an area health care policy could potentially address.
Read More